

Chlamydia trachomatis



When love makes you sick ...

Your fluorescence-based molecular genetic test system for the sensitive detection of *Chlamydia trachomatis* directly from patient specimens.



Your benefits of using FluoroType[®] CT

- **Highly sensitive and specific:** The simultaneous detection of two highly conserved target sequences, one within the genome and one within the cryptic plasmid, allows sensitive and reliable results.
- **User-friendly:** A ready-to-use amplification mix already including the Taq polymerase is provided with each kit. Amplification and detection run fully automated in a closed system. Interpretation of results is performed by the test-specific **FluoroSoftware**.
- **Innovative:** The **FluoroType[®]** technology allows for rapid and reliable results for efficient laboratory diagnostics.
- **Compatible with FluoroType[®] NG:** The DNA isolated with **FluoroLyse** can also be used for the detection of *Neisseria gonorrhoeae*.
- **CE₀₄₈₃-IVD certified:** No need for elaborate validation studies!

Facts

Urogenital *Chlamydia trachomatis* infection is one of the most prevalent sexually transmitted diseases worldwide. As the course of disease is frequently asymptomatic, the infection is not diagnosed and the bacteria are transmitted via sexual intercourse. If chlamydia infections are not treated, they can lead to pelvic inflammatory disease, ectopic pregnancy or infertility. Mainly young adults between 15 and 24 years of age are affected, but incidence and prevalence vary between 1% and 40% depending on region and patient population. However, a general increase in the number of cases was observed in recent years.

FluoroType® CT – Rapid, smart and cost-efficient!

As highly specific nucleic acid amplification test, **FluoroType® CT** allows the reliable detection of *C. trachomatis* directly from cervical swabs, first-void urine and ejaculate within three hours. To ensure a sensitive pathogen identification, **FluoroType® CT** simultaneously detects two different target sequences, one within the genome and another one in the cryptic plasmid. Therefore, the new *C. trachomatis* variant, which was discovered in Sweden in 2006, as well as cryptic plasmid-free chlamydia can be detected. The assay can be implemented in your laboratory routine in an easy and cost-efficient manner. Furthermore, DNA extracted for determining *C. trachomatis* can also be used for **FluoroType® NG** to identify *Neisseria gonorrhoeae* infections. Both tests can simultaneously be processed in the **FluoroCycler®**.


Test principle of FluoroType® CT



DNA extraction



Amplification and detection



Results in approx. 3 hours

Innovative technology

For **FluoroType® CT** bacterial DNA is extracted from the sample material. The subsequent amplification and detection run fully automated in the **FluoroCycler®** instruments. The evaluation and result interpretation is performed by the test-specific **FluoroSoftware**. This guarantees maximum user-friendliness and efficient laboratory diagnostics with impeccable results at a glance.

For further information please contact Hain Lifescience or your local distributor.

Hain Lifescience GmbH

Hardwiesenstrasse 1 | 72147 Nehren | Germany
Tel.: +49 (0) 74 73- 94 51- 0 | Fax: +49 (0) 74 73- 94 51- 31
E-Mail: info@hain-lifescience.de | www.hain-lifescience.de



A Bruker Company